Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma (2011)

Peer-Reviewed Study · Dobrosotskaya IY, Hammer GD, Schteingart DE, Maturen KE, Worden FP · May 2011

Dobrosotskaya IY et al., 2011-05: Single-patient case report of a 48-year-old man with metastatic adrenocortical carcinoma whose disease remained stable for 19 months on mebendazole 100 mg twice daily after conventional therapies failed. His disease progressed after 24 months.

he was prescribed mebendazole, 100 mg twice daily, as a single agent. His metastases initially regressed and subsequently remained stable.

n/a

Dobrosotskaya IY et al., 2011-05: Single-patient case report of a 48-year-old man with metastatic adrenocortical carcinoma whose disease remained stable for 19 months on mebendazole 100 mg twice daily after conventional therapies failed. His disease progressed after 24 months. Study type: case report. N=1. Country: United States (University of Michigan). Dose: mebendazole 100 mg orally twice daily (200 mg/day), monotherapy. Duration: 24 months. Funder: not stated in the abstract. Conflicts: not stated in the PubMed record. Maker: not stated. Comparator: none; the patient had progressed on mitotane, 5-fluorouracil, streptozotocin, bevacizumab and radiation. Outcome: regression then stability for 19 months; progression at 24 months; no clinically significant adverse effects. Study type: case report.